Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
New in the 10-K 23 paragraphs with nothing like them in the 10-K filed Feb 26, 2025 New in the 10-Q 59 paragraphs not in the 10-Q filed Aug 3, 2026 10-Q against the 10-K 8 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 26, 2025. A box jumps to the paragraph as filed, below.

23 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

23 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 26, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

with each of the ten companies seeking to market a generic version of Epidiolex in the U.S. by granting each of the Epidiolex ANDA Filers a license to manufacture, market, and sell its own generic version of Epidiolex beginning in the very late 2030s, or earlier under certain circumstances, including but not limited to the launch of another generic Epidiolex product or a final decision that all unexpired claims of the Epidiolex patents are not infringed, or are invalid and/or unenforceable. However, these settlements do not prevent other third parties from filing additional ANDAs seeking to market a generic version of Epidiolex in the future. Any such filings could result in additional patent litigation or challenges with respect to Epidiolex and could require substantial financial resources. An adverse outcome in any such litigation, or the entry into additional settlement agreements, could result in the approval and commercialization of generic versions of Epidiolex earlier than anticipated and may have a material adverse effect on our businesses, financial condition, results of operations and growth prospects.

Read in the 10-K

On July 4, 2025, President Trump signed into law the OBBBA, which includes significant changes to Medicaid, Medicare, and the ACA. These reforms are anticipated to decrease federal health care spending by approximately $1 trillion by significantly reducing Medicaid spending and enrollment, making changes to the Medicare program, and altering ACA marketplace enrollment provisions. Such decreases to federal health care spending and loss of health care coverage could reduce access to, and reimbursement for, our products, which could have a negative adverse effect on our revenues.

Read in the 10-K

MFN pricing models have remained an area of significant interest to the Trump Administration. On July 31, 2025, President Trump issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025 executive order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. The letters also urged these companies to stipulate that they will not offer other developed nations better prices for new drugs than the prices offered for such products in the U.S. The letters called for engagement with FDA and CMS within 60 days to implement these changes and threatened to use “every tool in our arsenal” to address what the letter characterized as “abusive drug pricing practices”. Further, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer Medicaid programs prescription drug MFN pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. As of January 2026, 16 of the 17 pharmaceutical companies that received the July 2025 letters from President Trump have signed agreements with the Trump Administration.

On November 6, 2025, CMS announced the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model, a model under which participating manufacturers may voluntarily offer MFN pricing to state Medicaid programs for covered outpatient drugs. On December 19, 2025, CMS issued proposed rules to establish the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, two mandatory MFN pricing models impacting Part B drugs and Part D drugs in select geographic areas, respectively. Under the proposed rules, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other economically comparable reference countries, with an initial list of 19 reference countries included in the proposed rule.

Read in the 10-K

could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need.

Read in the 10-K

While we are an Irish company headquartered in Dublin, Ireland, we derive the majority of our revenues from sales of our products in the U.S. We conduct business globally and our operations, including third-party suppliers, span numerous countries outside the U.S. In particular, we have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing and development facility in Kent Science Park, U.K. where we produce Epidiolex/Epidyolex, and a manufacturing plant in Villa Guardia, Italy where we produce defibrotide drug substance. In addition, we rely on our supplier in the PRC for the manufacture of Ziihera.

The ongoing trade tensions between the U.S. and other jurisdictions have resulted in multiple rounds of tariffs and anticipated tariffs affecting pharmaceuticals and pharmaceutical ingredients, including finished drug products, manufacturing equipment, and related supplies. Such tariffs may significantly increase our costs for certain products. The Bureau of Industry and Security, U.S. Department of Commerce, has initiated an investigation to determine whether pharmaceutical ingredients, including finished drug product, manufactured outside the U.S. pose a national security risk and should be subject to additional tariffs. Should current tariffs hold or additional tariffs be imposed specifically targeting pharmaceutical imports, such tariffs will result in additional costs on our business, including costs with respect to APIs and other raw materials upon which our business depends and will generally increase our manufacturing costs. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Moreover, other governments have imposed and may continue to impose retaliatory tariffs, trade restrictions or trade barriers on our products, which may impose additional costs and complexity on our business. In addition, the dynamic and unpredictable tariff and trade landscape creates substantial uncertainty and significant planning challenges for our operations. Changes in tariff classifications, country-of-origin requirements or customs procedures can occur with limited notice. This uncertainty complicates our long-term investment decisions regarding manufacturing facilities, supply chain optimization, and R&D locations.

Read in the 10-K
Show the other 12

On April 21, 2025, we completed the acquisition of all the outstanding shares of Chimerix Common Stock. As a result of this, Chimerix became our indirect wholly owned subsidiary. The success of the acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our and Chimerix’s operations and we plan on devoting significant management attention and resources to integrating our business practices and operations with Chimerix’s so that we can fully realize the anticipated benefits of the acquisition. In addition, Modeyso, which we acquired in the acquisition, may not be successful or may require significantly greater resources and investments than originally anticipated. As a result, the anticipated benefits of the acquisition may not be realized fully within the expected timeframe or at all or may take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Read in the 10-K

intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.

Read in the 10-K

methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do.

Read in the 10-K

In December 2025, the European Parliament and the Council of the EU reached a provisional agreement on the revision of the existing EU pharmaceutical legislation, including the pediatric and orphan regulations. Under new legislation, there are some changes to the regulatory exclusivity periods. The provisional agreement is still pending formal approval by the

European Parliament and the Council of the EU and subsequent publication in the Official Journal of the EU. Dependent on the final version of the text, the new legislation could impact our ability to secure orphan designation for future products, and would impact the scope and duration of market and orphan exclusivities in the EU. The new legislation could impact our ability to maintain marketing exclusivity for future products in all EU member states if we are unable to meet certain access obligations or if we are unable to supply sufficient quantities of our product in all member states.

Read in the 10-K

attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised.

Read in the 10-K

We are adopting and exploring the use of AI technologies in our business, which introduces new risks and uncertainties. These include potential inaccuracies or biases in AI outputs, cybersecurity vulnerabilities, and evolving global regulatory requirements governing AI use. Reliance on flawed outputs could result in lower quality decision-making or prevent us from effectively utilizing AI in our business. We may also become vulnerable to operational disruptions if the AI technologies we use experience downtimes or are compromised by cyberattacks. If we do not effectively implement guardrails and train our employees or contractors on the safe and proper use of AI, or if our employees or contractors fail to effectively adhere to our established guardrails and training on the use of AI, we may experience adverse effects on our business, including data breaches, the loss of confidential information (including our intellectual property), unintentional disclosure of personal data, or other misuse of our proprietary information. Further, several governments and regulatory authorities have proposed or passed laws and regulations governing the use of AI. For example, in March 2024, the European Parliament adopted the AI Act that provides for EU-wide rules on data quality, transparency, human oversight and accountability with respect to the use of AI. In April 2024, the EU also revised its Cybersecurity Directive NIS2 rules that create new cybersecurity risk management and reporting obligations. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.

Read in the 10-K

in our revenues from the affected products and harm to our reputation and could have a significant impact on our sales, business and financial condition.

Read in the 10-K

Many companies have faced government investigations or lawsuits by whistleblowers who bring a qui tam action under the False Claims Act on behalf of themselves and the government for a variety of alleged improper marketing activities, including providing free product to customers expecting that the customers would bill federal programs for the product,

Read in the 10-K

Moreover, as a result of the broad scale release and availability of AI technologies such as generative AI, there is a global trend towards more regulation (e.g., the EU AI Act and AI laws passed in U.S. states) to ensure the ethical use, privacy, and security of AI and the data that it processes. Compliance with such laws will likely be an increasing and substantial cost in the future.

Disruptions at FDA, the SEC and other government agencies and regulatory authorities including due to a reduction in such agencies’ workforces, inadequate funding or the current and potential future government shutdowns, could prevent those agencies from performing normal functions on which our business relies, which could negatively impact our business.

The ability of FDA to review and approve new products or review other regulatory submissions can be affected by a variety of factors, including statutory, regulatory and policy changes, inadequate government budget and funding levels, government shutdowns, a reduction in FDA’s workforce and its ability to hire and retain key personnel. Disruptions at FDA and other agencies may also increase the time to meet with and receive agency feedback, review and/or approve our submissions, conduct inspections, issue regulatory guidance, or take other actions that facilitate the development, approval and marketing of regulated products, which would adversely affect our business. In addition, government proposals to reduce or eliminate budgetary deficits may include reduced allocations to FDA, the SEC and other government agencies and regulatory authorities on which our operations may rely. For example, in October 2025, the U.S. government shut down for 43 days and certain regulatory agencies, including FDA, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs again in the future, it could significantly impact the ability of FDA to review and process our regulatory submissions, which could have a material adverse effect on our business. It is unclear how these executive actions or other potential actions by the Trump Administration or other parts of the federal government will impact FDA, the SEC or other regulatory authorities that oversee our business. The reductions in FDA’s workforce and budgetary pressures could

significantly impact the ability of FDA to timely review and process our regulatory submissions or take other actions critical to the marketing of our products which could have a material adverse effect on our business.

Read in the 10-K

HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities. Implementation of this regulation could affect our obligations and potential liability under the 340B program in ways we cannot anticipate. We are also required

Read in the 10-K

In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.

Read in the 10-K

requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 2, 2026 that were not in the one before

New in the latest 10-Q

59 paragraphs in the 10-Q filed Nov 2, 2026 with nothing like them in the 10-Q filed Aug 3, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

In September 2026, we completed the acquisition of Actio, a privately-held company for an upfront payment of $ 820.0 million, net of cash acquired, with a potential for an additional payment of up to $ 500.0 million upon the achievement of certain regulatory and commercial milestones, for a total potential consideration of $ 1.3 billion. The acquisition was funded with existing cash and cash equivalents. As a result of the acquisition, we added ABS-1230 (JZP6979), a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor, to our clinical pipeline and Actio became our wholly owned subsidiary.

Read in the 10-Q

As part of the transaction, Actio spun out a new privately-held entity to which certain non-ABS-1230 (JZP6979) programs of Actio were transferred. The new, independent private company is funded by existing investors, with us receiving a minority stake and certain related rights.

Read in the 10-Q

The Actio Acquisition was accounted for as an asset acquisition because it did not meet the definition of a business.

Read in the 10-Q

The total consideration paid and the allocation to assets acquired and liabilities assumed was (in millions):

Read in the 10-Q

Consideration Upfront payment $ 820.0 Cash acquired 19.9 Total cash consideration paid to Actio 839.9 Transaction costs 10.8 Total consideration $ 850.7 Assets Acquired and Liabilities Assumed In-process research and development $ 754.2 Deferred tax asset 57.6 Equity investment 24.1 Cash 19.9 Accrued liabilities (6.6) Other assets and liabilities 1.5 Total net assets acquired $ 850.7

Read in the 10-Q
Show the other 54

The value attributed to IPR&D related to ABS-1230 (JZP6979) and was expensed as it was determined to have no alternative future use at the time of the acquisition.

Read in the 10-Q

Balance at December 31, 2025 $1,829.3 Foreign exchange (26.5) Balance at September 30, 2026 $1,802.8

Read in the 10-Q

On May 5, 2021, Jazz Pharmaceuticals plc, Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with Jazz Pharmaceuticals plc and Jazz Lux, the “Borrowers”, entered into the Credit Agreement. The Credit Agreement initially provided for (i) the Dollar Term Loan, which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) the Euro Term Loan, which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) the Initial Revolving Credit Facility.

Read in the 10-Q

The Borrowers have entered into amendments to reprice the Term Loans in January 2024 (Amendment No. 1), July 2024 (Amendment No. 2) and in September 2026 (Amendment No. 4) pursuant to which the outstanding Term Loans were converted into, and/or repaid with the proceeds, of a new tranche of dollar term loans. Most recently in September 2026, the Borrowers entered into an Amendment No. 4 to the Credit Agreement pursuant to which the then outstanding Tranche B-2 Dollar Term Loans were converted into, and/or repaid with the proceeds of Tranche B-3 Dollar Term Loans. In addition, in November 2024, the Borrowers entered into Amendment No. 3 to the Credit Agreement, to increase the Initial Revolving Credit Facility from $ 500.0 million to $ 885.0 million and extend the maturity date thereof from May 5, 2026 to November 26, 2029.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement, with substantially the same material terms (including with respect to prepayment, security, covenants and events of default) as the previously outstanding Tranche B-2 Dollar Term Loans incurred on July 19, 2024, the Tranche B-1 Dollar Term Loans incurred on January 19, 2024, and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below. The principal amount of Tranche B-2 Dollar Term Loans outstanding immediately prior to the Amendment No. 4 and the outstanding principal amount of Tranche B-3 Dollar Term Loans immediately following the Amendment No.4, each totaled $ 1.9 billion.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-3 Dollar Term Loans is 1.75 % (in the case of Term SOFR borrowings) and 0.75 % (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Tranche B-2 Dollar Term Loans. The Tranche B-3 Dollar Term Loans are subject to a Term SOFR

Read in the 10-Q

floor of 0.50 %. As of September 30, 2026, the interest rate and effective interest rate on the Tranche B-3 Dollar Term Loans were 5.65 % and 5.94 %, respectively.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans will amortize in quarterly installments equal to 0.25 % of the initial principal amount thereof, with the remaining balance payable on May 5, 2033.

Read in the 10-Q

Interest on the 2032 Notes is payable semi-annually in cash in arrears on March 15 and September 15 of each year, beginning on March 15, 2027, at a rate of 1.875 % per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2032 Notes. The 2032 Notes mature on September 15, 2032, unless earlier exchanged, redeemed or repurchased.

Read in the 10-Q

The holders of the 2032 Notes have the ability to require us to repurchase all or a portion of their 2032 Notes for cash at a fundamental change repurchase price equal to 100 % of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2032 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors).

Read in the 10-Q

Additionally, the terms and covenants in the indenture related to the 2032 Notes include certain events of default after which the 2032 Notes may be due and payable immediately.

Read in the 10-Q

Prior to September 15, 2032, we may redeem the 2032 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2032 Notes on or after September 20, 2029, in whole or in part (subject to the partial redemption limitation described below and in the indenture related to the 2032 Notes), if the last reported sale price of the ordinary shares has been at least 130 % of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption. Subject to the conditions described in the indenture related to the 2032 Notes, we may also redeem all, but not less than all, of the 2032 Notes at our option at any time if the principal amount of the 2032 Notes outstanding at such time is less than $ 100.0 million. The redemption price for any redemption will be 100 % of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

Read in the 10-Q

The exchange rate for the 2032 Notes is initially 2.8150 ordinary shares per $1,000 principal amount of 2032 Notes, which is equivalent to an initial exchange price of approximately $ 355.24 per ordinary share. Upon exchange of the 2032 Notes, we will pay cash up to the aggregate principal amount of the 2032 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2032 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2032 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2032 Notes in connection with that make-whole fundamental change or exchange its 2032 Notes called (or deemed called, in the case of an optional redemption) for redemption during the related redemption period, as the case may be. Prior to June 15, 2032, the 2032 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

Read in the 10-Q

On October 14, 2025, Praxis filed a lawsuit in the U.S. District Court for the District of Delaware against Actio and David B. Goldstein, Ph. D., Actio's co-founder and former CEO. The complaint alleges, among other things, that Dr. Goldstein breached a Master Advisory Agreement with Praxis and that Actio and Dr. Goldstein misappropriated Praxis' trade secrets relating to certain KCNT1 inhibitor compounds. Praxis seeks declaratory relief, injunctive relief, assignment of intellectual property allegedly derived from Praxis’ confidential and trade secret information, unspecified compensatory and exemplary damages, attorneys’ fees and costs, and an accounting and disgorgement of defendants’ alleged unjust enrichment.

Read in the 10-Q

On December 5, 2025, defendants filed a joint motion to dismiss the complaint, which the U.S. District Court for the District of Delaware denied on September 3, 2026. On September 24, 2026, we filed our answer to the complaint and affirmative defenses. Trial in this matter is scheduled to begin July 31, 2028. We will continue to vigorously defend against these claims.

Read in the 10-Q

revenues, costs and foreign currency exchange rates. We will continue to monitor changes in law and guidance in relation to Pillar Two.

Read in the 10-Q

In combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab-jsgr, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.

Read in the 10-Q

In August 2026, FDA approved two Ziihera-containing regimens for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA: Ziihera plus tislelizumab and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ or IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC3+). Ziihera was launched in GEA following its approval for patients with this aggressive and difficult-to-treat cancer. Through Project Orbis, we completed applications of Ziihera for the same indication to MHRA and Health Canada.

Read in the 10-Q

Modeyso is licensed to Ohara Pharmaceutical Co., Ltd. in Japan and was approved by the Ministry of Health, Labour and Welfare in September 2026, for the treatment of diffuse midline glioma. We are eligible to receive tiered royalties on annual net sales in Japan.

Read in the 10-Q

Expanding the breadth of our presence in epilepsy treatment, we announced a definitive agreement to acquire Actio in August 2026. At the center of the Actio Acquisition is ABS-1230 (JZP6979), a clinical-stage, novel, small molecule precision therapy designed to selectively inhibit the KCNT1 ion channel. Regulatory agencies have recognized the potential of ABS-1230 (JZP6979) by granting fast track, rare pediatric disease and orphan drug product designations. ABS-1230 (JZP6979) is advancing in the Phase 1b/2a KYRON trial, which is structured as a registrational trial and could support a future NDA submission.

Read in the 10-Q

We completed the Actio Acquisition in September 2026, for an upfront payment of $820.0 million, net of cash acquired, with the potential for additional payments of up to $500.0 million upon the achievement of certain regulatory and commercial milestones, for a total potential consideration of $1.3 billion.

Read in the 10-Q

In September 2026, we received IND clearance for JZP269, a differentiated orexin-2 receptor agonist, and initiated a Phase 1 first-in-human trial to evaluate the safety, tolerability and wake-promoting effects of JZP269 in sleep-deprived healthy participants.

Read in the 10-Q

Moreover, the U.S. government has imposed and may seek to impose additional restrictions on international trade, such as tariffs on goods generally, and pharmaceutical and biological products in particular, imported into the U.S. In April 2026,

Read in the 10-Q

On May 5, 2021, Jazz Pharmaceuticals plc, Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with Jazz Pharmaceuticals plc and Jazz Lux, the “Borrowers”, entered into the Credit Agreement. The Credit Agreement

Read in the 10-Q

initially provided for (i) the Dollar Term Loan, which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) the Euro Term Loan, which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) the Initial Revolving Credit Facility.

Read in the 10-Q

The Borrowers have entered into amendments to reprice the Term Loans in January 2024 (Amendment No. 1), July 2024 (Amendment No. 2) and in September 2026 (Amendment No. 4) pursuant to which the outstanding Term Loans were converted into, and/or repaid with the proceeds, of a new tranche of dollar term loans. Most recently in September 2026, the Borrowers entered into an Amendment No. 4 to the Credit Agreement pursuant to which the then outstanding Tranche B-2 Dollar Term Loans were converted into, and/or repaid with the proceeds of Tranche B-3 Dollar Term Loans. In addition, in November 2024, the Borrowers entered into Amendment No. 3 to the Credit Agreement, to increase the Initial Revolving Credit Facility from $500.0 million to $885.0 million and extend the maturity date thereof from May 5, 2026 to November 26, 2029.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement, with substantially the same material terms (including with respect to prepayment, security, covenants and events of default) as the previously outstanding Tranche B-2 Dollar Term Loans incurred on July 19, 2024, the Tranche B-1 Dollar Term Loans incurred on January 19, 2024, and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below. The principal amount of Tranche B-2 Dollar Term Loans outstanding immediately prior to the Amendment No. 4 and the outstanding principal amount of Tranche B-3 Dollar Term Loans immediately following the Amendment No.4, each totaled $1.9 billion.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-3 Dollar Term Loans is 1.75% (in the case of Term SOFR borrowings) and 0.75% (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Tranche B-2 Dollar Term Loans. The Tranche B-3 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. As of September 30, 2026, the interest rate and effective interest rate on the Tranche B-3 Dollar Term Loans were 5.65% and 5.94%, respectively.

Read in the 10-Q

The Tranche B-3 Dollar Term Loans will amortize in quarterly installments equal to 0.25% of the initial principal amount thereof, with the remaining balance payable on May 5, 2033.

Read in the 10-Q

Interest on the 2032 Notes is payable semi-annually in cash in arrears on March 15 and September 15 of each year, beginning on March 15, 2027, at a rate of 1.875% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2032 Notes. The 2032 Notes mature on September 15, 2032, unless earlier exchanged, redeemed or repurchased.

Read in the 10-Q

The holders of the 2032 Notes have the ability to require us to repurchase all or a portion of their 2032 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2032 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors).

Read in the 10-Q

Additionally, the terms and covenants in the indenture related to the 2032 Notes include certain events of default after which the 2032 Notes may be due and payable immediately.

Read in the 10-Q

Prior to September 15, 2032, we may redeem the 2032 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2032 Notes on or after September 20, 2029, in whole or in part (subject to the partial redemption limitation described below and in the indenture related to the 2032 Notes), if the last reported sale price of the ordinary shares has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption. Subject to the conditions described in the indenture related to the 2032 Notes,

Read in the 10-Q

we may also redeem all, but not less than all, of the 2032 Notes at our option at any time if the principal amount of the 2032 Notes outstanding at such time is less than $100.0 million. The redemption price for any redemption will be 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

Read in the 10-Q

The exchange rate for the 2032 Notes is initially 2.8150 ordinary shares per $1,000 principal amount of 2032 Notes, which is equivalent to an initial exchange price of approximately $355.24 per ordinary share. Upon exchange of the 2032 Notes, we will pay cash up to the aggregate principal amount of the 2032 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2032 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2032 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2032 Notes in connection with that make-whole fundamental change or exchange its 2032 Notes called (or deemed called, in the case of an optional redemption) for redemption during the related redemption period, as the case may be. Prior to June 15, 2032, the 2032 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

Read in the 10-Q

• We may not realize the anticipated benefits from our acquisitions, including the Actio Acquisition.

Read in the 10-Q

Risk Factors

We may not realize the anticipated benefits from our acquisitions, including the Actio Acquisition.

Read in the 10-Q

Our ability to realize the anticipated benefits from our acquisitions, including the Actio Acquisition, is subject to numerous risks and uncertainties. The success of any acquisition will depend in part, on our ability to successfully integrate the acquired businesses, assets, products, product candidates, technologies and operations into our existing business and to achieve the anticipated strategic, operational and financial benefits of such acquisitions. The anticipated benefits of our acquisitions are based on assumptions and expectations that may prove to be inaccurate or incomplete. In addition, difficulties may arise during the process of combining the operations of acquired businesses that could result in the failure to achieve anticipated revenue, delays or failures in the development, regulatory approval or commercialization of product candidates, the loss of key employees that may be difficult to replace in the very competitive pharmaceutical field, the failure to harmonize the companies’ corporate cultures, the disruption of ongoing businesses or inconsistencies in standards, controls, procedures and policies that adversely affect our ability to maintain relationships with suppliers, collaboration partners, clinical trial investigators or managers of our clinical trials. Acquisitions may also involve unexpected costs, liabilities, regulatory or legal risks, intellectual property disputes, or the need for additional investments and resources beyond those originally anticipated. As a result, the anticipated benefits of any acquisition may not be realized within the expected timeframe, or at all, and the costs associated with an acquisition may exceed our expectations, any of which could materially adversely affect our business, financial conditions, results of operations and growth prospects.

Read in the 10-Q

On September 15, 2026, we completed the Actio Acquisition for an upfront payment of $820.0 million, net of cash acquired, with the potential for additional payments of up to $500.0 million upon the achievement of certain regulatory and commercial milestones, for a total potential consideration of $1.3 billion. As a result, Actio became our wholly owned subsidiary. Our ability to realize the anticipated benefits of the Actio Acquisition will depend, in large part, on the successful development, receipt of regulatory approvals for and potential commercialization of ABS-1230 (JZP6979), which we acquired in the Actio Acquisition. ABS-1230 (JZP6979) may not be successfully developed, receive regulatory approval or be commercialized, may not achieve its anticipated commercial potential, or may require significantly greater resources and investments than originally anticipated.

Read in the 10-Q

In connection with the Actio Acquisition, we assumed a trade secret and breach of contract lawsuit brought by Praxis against Actio and its co-founder and Former CEO, Dr. Goldstein, in the U.S. District Court for the District of Delaware relating to certain KCNT1 inhibitor compounds. The complaint alleges, among other things, that Dr. Goldstein breached a Master Advisory Agreement with Praxis and that Actio and Dr. Goldstein misappropriated Praxis’ trade secrets relating to certain KCNT1 inhibitor compounds. Praxis seeks declaratory relief, injunctive relief, assignment of intellectual property allegedly derived from Praxis’ confidential and trade secret information, unspecified compensatory and exemplary damages, attorneys’ fees and costs, and an accounting and disgorgement of defendants’ alleged unjust enrichment. Although we intend to vigorously defend against these claims, intellectual property and trade secret disputes are inherently unpredictable and costly. An unfavorable ruling or settlement could result in substantial financial liabilities, require licensing arrangements on unfavorable terms, or result in an injunction or assignment of intellectual property that limits or precludes our ability to develop and commercialize ABS-1230 (JZP6979) or other acquired KCNT1 inhibitor assets, which would severely impair the expected value of the Actio Acquisition. For additional information regarding this litigation, see Note 10, Commitments and Contingencies - Legal Proceedings of the Notes to Condensed Consolidated Financial Statements, included in Part I of this Quarterly Report on Form 10-Q.

Read in the 10-Q

Our ability, and that of our partners, to successfully commercialize any approved products will depend, in part, on our ability to obtain patents, enforce those patents and operate without infringing the proprietary rights of third parties. If we choose to go to court to stop a third party from infringing our patents, our licensed patents or our partners’ patents, that third party has the right to ask the court or an administrative agency to rule that these patents are invalid and/or should not be enforced. For example, we are pursuing patent infringement proceedings in Germany initiated by Chimerix against a supplier in contravention of certain patents acquired in connection with the Chimerix Acquisition. These lawsuits and administrative proceedings are expensive and consume time and other resources, and we may not be successful in these proceedings or in stopping infringement. In addition, the IPR or a post-grant review process under the Leahy-Smith America Invents Act permits any person, whether they are accused of infringing the patent at issue or not, to challenge the validity of certain patents through a proceeding before the PTAB.

Read in the 10-Q

There is a risk that a court could decide that our patents or certain claims in our patents are not valid or infringed, and that we do not have the right to stop a third party from using the inventions covered by those claims. In addition, the PTAB may invalidate a patent, as happened with six of our patents covering the Xywav and Xyrem REMS that were invalidated through the IPR process. In addition, even if we prevail in establishing that another product infringes a valid claim of one of our patents, a court may determine that we can be compensated for the infringement in damages, and refuse to issue an injunction. As a result, we may not be entitled to stop another party from infringing our patents for their full term.

Read in the 10-Q

Parties to such settlement agreements in the U.S. are required by law to file the agreements with the FTC and the DOJ for review. Accordingly, we have submitted our patent litigation settlement agreements to the FTC and the DOJ for review. We may receive formal or informal requests from the FTC regarding our ANDA litigation settlements, and there is a risk that the FTC may commence a formal investigation or action against us, which could divert the attention of management and cause us to incur significant costs, regardless of the outcome. Any claim or finding that we or our business partners have failed to comply with applicable laws and regulations could be costly to us and have a material adverse effect on our business, financial condition, results of operations and growth prospects.

Read in the 10-Q

A third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party’s patent rights, or that we or such partners are infringing, misappropriating or otherwise violating other intellectual property rights, and may go to court to stop us from engaging in our normal operations and activities, including making or selling our products. For example, on October 14, 2025, Praxis filed a lawsuit in the U.S. District Court for the District of Delaware against Actio and David B. Goldstein, Ph. D., Actio's co-founder and former CEO. The complaint alleges, among other things, that Dr. Goldstein breached a Master Advisory Agreement with Praxis and that Actio and Dr. Goldstein misappropriated Praxis’ trade secrets relating to certain KCNT1 inhibitor compounds. Praxis seeks declaratory relief, injunctive relief, assignment of intellectual property allegedly derived from Praxis’ confidential and trade secret information, unspecified compensatory and exemplary damages, attorneys’ fees and costs, and an accounting and disgorgement of defendants’ alleged unjust enrichment.

Read in the 10-Q

On December 5, 2025, defendants filed a joint motion to dismiss the complaint, which the U.S. District Court for the District of Delaware denied on September 3, 2026. On September 15, 2026, in connection with the Actio Acquisition, we assumed Actio’s position as a defendant in this action, together with other rights and liabilities related to the acquired assets. On September 24, 2026, we filed our answer to the complaint and affirmative defenses. Trial in this matter is scheduled to begin July 31, 2028. Lawsuits such as these are costly and could affect our results of operations and divert the attention of management and development personnel. There is a risk that a court could decide that we or our partners are infringing, misappropriating or otherwise violating third party patent or other intellectual property rights, which could be very costly to us and have a material adverse effect on our business. If we are sued for patent infringement, we would need to demonstrate that our products or methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do.

Read in the 10-Q

If we were found to infringe upon a patent or other intellectual property right, if we failed to obtain or renew a license under a patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. In addition, if we have declined or failed to enter into a valid assignment agreement for any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected.

Read in the 10-Q

Litigation, whether filed by us or against us, can be expensive and time consuming to defend and divert management’s attention and resources. Our competitive position could suffer as a result.

Read in the 10-Q

Share sales and buybacks

The following table summarizes purchases of our ordinary shares made by or on behalf of us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended, during each fiscal month during the three-month period ended September 30, 2026:

Read in the 10-Q

Total Number of Shares Purchased (1) Average Price Paid per Share (2) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (3) Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (4)

Read in the 10-Q

1. This table does not include ordinary shares that we withheld in order to satisfy tax withholding requirements in connection with the vesting and release of restricted stock units. All the ordinary shares reported in this column were purchased pursuant to our publicly announced share Repurchase Program.

Read in the 10-Q

4. The dollar amount shown represents, as of the end of each period, the approximate dollar value, in millions, of ordinary shares that may yet be purchased under the Repurchase Program, exclusive of any brokerage commissions.

Read in the 10-Q

In October 2026, our board of directors approved a new share repurchase program to repurchase ordinary shares having an aggregate purchase price of $500.0 million, exclusive of any brokerage commissions.

Read in the 10-Q

Other information

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.

Read in the 10-Q

Item 6

‡ Portions of this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K because they are both not material and are the type that the Registrant treats as confidential.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 2, 2026 against Item 1A of the 10-K filed Feb 24, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Added10-Q Nov 2, 2026 vs 10-K Feb 24, 2026
Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Our risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, provide additional discussion regarding these supplemental risks and we encourage you to read and carefully consider all of the risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, together with the below, for a more complete understanding of the risks and uncertainties material to our business.

Read it in the 10-Q at sec.gov

Added10-Q Nov 2, 2026 vs 10-K Feb 24, 2026
Our ability to realize the anticipated benefits from our acquisitions, including the Actio Acquisition, is subject to numerous risks and uncertainties. The success of any acquisition will depend in part, on our ability to successfully integrate the acquired businesses, assets, products, product candidates, technologies and operations into our existing business and to achieve the anticipated strategic, operational and financial benefits of such acquisitions. The anticipated benefits of our acquisitions are based on assumptions and expectations that may prove to be inaccurate or incomplete. In addition, difficulties may arise during the process of combining the operations of acquired businesses that could result in the failure to achieve anticipated revenue, delays or failures in the development, regulatory approval or commercialization of product candidates, the loss of key employees that may be difficult to replace in the very competitive pharmaceutical field, the failure to harmonize the companies’ corporate cultures, the disruption of ongoing businesses or inconsistencies in standards, controls, procedures and policies that adversely affect our ability to maintain relationships with suppliers, collaboration partners, clinical trial investigators or managers of our clinical trials. Acquisitions may also involve unexpected costs, liabilities, regulatory or legal risks, intellectual property disputes, or the need for additional investments and resources beyond those originally anticipated. As a result, the anticipated benefits of any acquisition may not be realized within the expected timeframe, or at all, and the costs associated with an acquisition may exceed our expectations, any of which could materially adversely affect our business, financial conditions, results of operations and growth prospects.

Read it in the 10-Q at sec.gov

Added10-Q Nov 2, 2026 vs 10-K Feb 24, 2026
On September 15, 2026, we completed the Actio Acquisition for an upfront payment of $820.0 million, net of cash acquired, with the potential for additional payments of up to $500.0 million upon the achievement of certain regulatory and commercial milestones, for a total potential consideration of $1.3 billion. As a result, Actio became our wholly owned subsidiary. Our ability to realize the anticipated benefits of the Actio Acquisition will depend, in large part, on the successful development, receipt of regulatory approvals for and potential commercialization of ABS-1230 (JZP6979), which we acquired in the Actio Acquisition. ABS-1230 (JZP6979) may not be successfully developed, receive regulatory approval or be commercialized, may not achieve its anticipated commercial potential, or may require significantly greater resources and investments than originally anticipated.

Read it in the 10-Q at sec.gov

Added10-Q Nov 2, 2026 vs 10-K Feb 24, 2026
In connection with the Actio Acquisition, we assumed a trade secret and breach of contract lawsuit brought by Praxis against Actio and its co-founder and Former CEO, Dr. Goldstein, in the U.S. District Court for the District of Delaware relating to certain KCNT1 inhibitor compounds. The complaint alleges, among other things, that Dr. Goldstein breached a Master Advisory Agreement with Praxis and that Actio and Dr. Goldstein misappropriated Praxis’ trade secrets relating to certain KCNT1 inhibitor compounds. Praxis seeks declaratory relief, injunctive relief, assignment of intellectual property allegedly derived from Praxis’ confidential and trade secret information, unspecified compensatory and exemplary damages, attorneys’ fees and costs, and an accounting and disgorgement of defendants’ alleged unjust enrichment. Although we intend to vigorously defend against these claims, intellectual property and trade secret disputes are inherently unpredictable and costly. An unfavorable ruling or settlement could result in substantial financial liabilities, require licensing arrangements on unfavorable terms, or result in an injunction or assignment of intellectual property that limits or precludes our ability to develop and commercialize ABS-1230 (JZP6979) or other acquired KCNT1 inhibitor assets, which would severely impair the expected value of the Actio Acquisition. For additional information regarding this litigation, see Note 10, Commitments and Contingencies - Legal Proceedings of the Notes to Condensed Consolidated Financial Statements, included in Part I of this Quarterly Report on Form 10-Q.

Read it in the 10-Q at sec.gov

Show the other 3
Reworded10-Q Nov 2, 2026 vs 10-K Feb 24, 2026
If we are sued for patent infringement, we would need to demonstrate that our products or methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do.

Read it in the 10-Q at sec.govThe 10-K sentence

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 24, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 26, 2025

mfn pricing ×10alkermes lumryz ×5provisional agreement ×4tris pharma ×3settlement agreement ×3ziihera modeyso ×3developed nations ×3pricing models ×3president trump ×3trump administration ×3bulk sensitive ×3regulatory submissions ×3share issuance ×3harbor rules ×3lumryz acquired ×2orexin receptor ×2
Where each one is used
  • mfn pricing: The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, FDA, CMS and related agencies. These actions, primarily directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional...
  • alkermes lumryz: Historically, our business was substantially dependent on Xyrem, and our financial results were significantly influenced by sales of Xyrem. Our current 2026 operating plan assumes that Xywav, with 92% lower sodium compared to high-sodium oxybates (depending on the dose) and absence of a sodium warning, will remain...
  • provisional agreement: We expect that legislators, policymakers and healthcare insurance funds in Europe and other international markets will continue to propose and implement cost-containing measures to keep healthcare costs down. These measures could include limitations on the prices we will be able to charge for our products or the...
  • tris pharma: We expect that Xywav for the treatment of both cataplexy and EDS in patients with narcolepsy will continue to face competition from generic or AG high-sodium oxybate products or branded entrants in narcolepsy, such as Alkermes’ Lumryz, notwithstanding FDA recognizing ODE for Xywav. For example, we received notices...
  • settlement agreement: wholesalers or direct purchasers in the U.S. (without discounts, rebates or other reductions) referred to as the WAC. In this regard, Hikma and Amneal launched their AG products in 2023 at a WAC that was less than 15% lower than the WAC for Xyrem. After any introduction of a generic product, whether or not it is an...
  • ziihera modeyso: In addition to Xywav, Epidiolex/Epidyolex and our other neuroscience products and product candidates, we are commercializing a portfolio of products, including our other lead marketed products, Ziihera, Modeyso, Zepzelca and Rylaze. An inability to effectively commercialize our other lead marketed products and to...
  • developed nations: The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, FDA, CMS and related agencies. These actions, primarily directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional...
  • pricing models: rebates and penalties to government health care programs, and additional pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures. In addition, policymakers and federal agencies, including the Center for Medicare & Medicaid Innovation, are...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

8 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
on October 30, 2024, the District Court issued an order denying our motion for summary judgment and granting Avadel’s and FDA’s cross-motions for summary judgment. We have appealed the matter to the United States Court of Appeals for the District of Columbia Circuit. We cannot predict the timing or ultimate outcome of this litigation or the impact of this litigation on our business, including any potential adverse consequences to, among other things, our reputation, relationships with governmental or regulatory authorities, including FDA. For additional information, see "FDA Litigation" in...
In the 10-K filed Feb 26, 2025
take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In this regard, in the third quarter of 2022, we recorded a $133.6 million asset impairment charge as a result of the decision to discontinue the nabiximols program that we acquired as part of our acquisition of GW. In any event, failure to manage effectively our growth through acquisitions or in-licensing transactions could adversely affect our growth prospects, business, results of operations and financial condition.
In the 10-K filed Feb 26, 2025
distribution of our profits or losses between the jurisdictions where we operate and changes to or differences in interpretation of tax laws. For example, our income tax expense for the year ended December 31, 2021, included an expense of $259.9 million arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following enactment of the U.K. Finance Act 2021.
In the 10-K filed Feb 26, 2025
increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. Rebates are no longer subject to a cap on the rebate amount, which negatively impacts our rebate liability.
In the 10-K filed Feb 26, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.